Wells Fargo
CGTX icon

Wells Fargo’s Cognition Therapeutics CGTX Stock Holding History

Wells Fargo’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.32K Buy
3,050
+50
+2% +$58 ﹤0.01% 6234
2025
Q4 		$4.05K Sell
3,000
-1,000
-25% -$1.62K ﹤0.01% 6136
2025
Q3 		$5.4K Buy
4,000
+3,000
+300% +$4.09K ﹤0.01% 6063
2025
Q2 		$310 Hold
1,000
– – ﹤0.01% 6417
2025
Q1 		$421 Hold
1,000
– – ﹤0.01% 6278
2024
Q4 		$701 Hold
1,000
– – ﹤0.01% 6291
2024
Q3 		$469 Hold
1,000
– – ﹤0.01% 6176
2024
Q2 		$1.66K Buy
1,000
+854
+585% +$1.7K ﹤0.01% 6044
2024
Q1 		$266 Buy
146
+10
+7% +$21 ﹤0.01% 6431
2023
Q4 		$252 Buy
136
+8
+6% +$11 ﹤0.01% 6548
2023
Q3 		$184 Sell
128
-9
-7% -$14 ﹤0.01% 6607
2023
Q2 		$251 Buy
137
+13
+10% +$28 ﹤0.01% 6636
2023
Q1 		$246 Sell
124
-38,386
-100% -$73.1K ﹤0.01% 6720
2022
Q4 		$80.9K Sell
38,510
-38,417
-50% -$77.6K ﹤0.01% 4638
2022
Q3 		$146K Buy
76,927
+60
+0.1% +$125 ﹤0.01% 4411
2022
Q2 		$162K Buy
76,867
+76,843
+320,179% +$199K ﹤0.01% 4393
2022
Q1 		$0 Hold
24
– – ﹤0.01% 7116
2021
Q4 		$0 Buy
+24
New +$234 ﹤0.01% 7261

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Wells Fargo's CGTX Position: Q1 2026 in Review

Wells Fargo increased its Cognition Therapeutics (CGTX) stake by 1.7% in Q1 2026, buying an estimated $58 and bringing the position to 3,050 shares worth $2.32K. The position accounts for ﹤0.01% of the portfolio, ranked #6234.

Wells Fargo first reported a position in CGTX in Q4 2021 and has held it in 18 quarters since. The position peaked at $162K in Q2 2022. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Wells Fargo held 3,050 shares of Cognition Therapeutics worth $2.32K as of Q1 2026.
  • Wells Fargo bought 50 Cognition Therapeutics shares in Q1 2026, an estimated $58.
  • Cognition Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6234 holding.
  • Wells Fargo first reported a position in Cognition Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Wells Fargo's Cognition Therapeutics position peaked at $162K in Q2 2022.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.